CN103159680A - 咪唑二酮类化合物及其用途 - Google Patents

咪唑二酮类化合物及其用途 Download PDF

Info

Publication number
CN103159680A
CN103159680A CN2011104188590A CN201110418859A CN103159680A CN 103159680 A CN103159680 A CN 103159680A CN 2011104188590 A CN2011104188590 A CN 2011104188590A CN 201110418859 A CN201110418859 A CN 201110418859A CN 103159680 A CN103159680 A CN 103159680A
Authority
CN
China
Prior art keywords
compound
deuterium
generation
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011104188590A
Other languages
English (en)
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMYNIDY PHARMACEUTICAL Co Ltd
Original Assignee
AMYNIDY PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMYNIDY PHARMACEUTICAL Co Ltd filed Critical AMYNIDY PHARMACEUTICAL Co Ltd
Priority to CN2011104188590A priority Critical patent/CN103159680A/zh
Priority to CA2859224A priority patent/CA2859224C/en
Priority to ES12858174.1T priority patent/ES2587903T3/es
Priority to US14/364,147 priority patent/US9346764B2/en
Priority to AU2012350482A priority patent/AU2012350482B2/en
Priority to PCT/CN2012/086573 priority patent/WO2013087004A1/zh
Priority to CN201280052853.9A priority patent/CN104024228B/zh
Priority to EP12858174.1A priority patent/EP2792674B1/en
Priority to HK14111671.7A priority patent/HK1198166B/en
Priority to JP2014546301A priority patent/JP5933746B2/ja
Priority to PL12858174.1T priority patent/PL2792674T3/pl
Publication of CN103159680A publication Critical patent/CN103159680A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011104188590A 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途 Pending CN103159680A (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
CA2859224A CA2859224C (en) 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses
ES12858174.1T ES2587903T3 (es) 2011-12-14 2012-12-13 Compuestos de imidazolidinadiona y sus usos
US14/364,147 US9346764B2 (en) 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses
AU2012350482A AU2012350482B2 (en) 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses
PCT/CN2012/086573 WO2013087004A1 (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途
CN201280052853.9A CN104024228B (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途
EP12858174.1A EP2792674B1 (en) 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses
HK14111671.7A HK1198166B (en) 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses
JP2014546301A JP5933746B2 (ja) 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途
PL12858174.1T PL2792674T3 (pl) 2011-12-14 2012-12-13 Związki imidazolidynodionu i ich zastosowania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途

Publications (1)

Publication Number Publication Date
CN103159680A true CN103159680A (zh) 2013-06-19

Family

ID=48583248

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011104188590A Pending CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
CN201280052853.9A Active CN104024228B (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280052853.9A Active CN104024228B (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Country Status (9)

Country Link
US (1) US9346764B2 (https=)
EP (1) EP2792674B1 (https=)
JP (1) JP5933746B2 (https=)
CN (2) CN103159680A (https=)
AU (1) AU2012350482B2 (https=)
CA (1) CA2859224C (https=)
ES (1) ES2587903T3 (https=)
PL (1) PL2792674T3 (https=)
WO (1) WO2013087004A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
CN106432090A (zh) * 2015-10-30 2017-02-22 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
WO2018072300A1 (zh) * 2016-10-17 2018-04-26 成都海创药业有限公司 一种制备氘代咪唑二酮类化合物的方法
WO2019196945A1 (zh) * 2018-04-13 2019-10-17 成都海创药业有限公司 一种合成氘代酰胺及氘代磺酰胺的新方法
WO2021037198A1 (zh) * 2019-08-30 2021-03-04 润佳（苏州）医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043A (zh) * 2022-07-27 2022-10-14 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6469092B2 (ja) * 2013-05-29 2019-02-13 ヒノバ ファーマシューティカルズ インコーポレイテッド イミダゾリジンジオン化合物及び薬物組成物
AU2014321456B2 (en) * 2013-09-19 2018-05-24 Glaxosmithkline Llc Combination drug therapy
WO2016051423A2 (en) * 2014-10-01 2016-04-07 Laurus Labs Private Limited An improved process for the preparation of enzalutamide
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
AU2017202864B2 (en) * 2017-02-13 2020-04-23 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AU2019241257B2 (en) * 2018-03-29 2025-02-20 Hinova Pharmaceuticals Inc. Deuterated imidazolidinedione compounds and their uses
CA3105389C (en) * 2018-05-14 2025-05-20 Hinova Pharmaceuticals Inc. A formulation of hc-1119 as well as the production method and the use thereof
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
WO2021185291A1 (zh) * 2020-03-17 2021-09-23 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
CA3188821A1 (en) 2020-08-13 2022-02-17 Lars ANDERS Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
WO2011029392A1 (en) 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
CN106432090A (zh) * 2015-10-30 2017-02-22 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN106432090B (zh) * 2015-10-30 2019-08-20 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
WO2018072300A1 (zh) * 2016-10-17 2018-04-26 成都海创药业有限公司 一种制备氘代咪唑二酮类化合物的方法
WO2019196945A1 (zh) * 2018-04-13 2019-10-17 成都海创药业有限公司 一种合成氘代酰胺及氘代磺酰胺的新方法
CN110372598A (zh) * 2018-04-13 2019-10-25 成都海创药业有限公司 一种合成氘代酰胺及氘代磺酰胺的新方法
US11753392B2 (en) 2018-04-13 2023-09-12 Hinova Pharmaceuticals Inc. Method for synthesis of deuterated amide and deuterated sulfonamide
WO2021037198A1 (zh) * 2019-08-30 2021-03-04 润佳（苏州）医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043A (zh) * 2022-07-27 2022-10-14 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Also Published As

Publication number Publication date
CN104024228A (zh) 2014-09-03
EP2792674B1 (en) 2016-05-25
HK1198166A1 (en) 2015-03-13
CA2859224A1 (en) 2013-06-20
EP2792674A4 (en) 2015-06-17
EP2792674A1 (en) 2014-10-22
WO2013087004A1 (zh) 2013-06-20
US20140371284A1 (en) 2014-12-18
JP2015501820A (ja) 2015-01-19
CN104024228B (zh) 2015-07-08
CA2859224C (en) 2019-03-19
AU2012350482A1 (en) 2014-07-10
US9346764B2 (en) 2016-05-24
PL2792674T3 (pl) 2016-12-30
AU2012350482B2 (en) 2017-02-16
ES2587903T3 (es) 2016-10-27
JP5933746B2 (ja) 2016-06-15

Similar Documents

Publication Publication Date Title
CN103159680A (zh) 咪唑二酮类化合物及其用途
CN102190616B (zh) 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
CN104211683B (zh) 咪唑二酮类化合物及其用途
CN104024262A (zh) 埃克替尼和盐酸埃克替尼的制备方法及其中间体
CN110551145B (zh) 一类呋喃并香豆素-Tröger’s Base衍生物及其合成方法与应用
CN104277029B (zh) 吖啶-1，2，3-三唑类化合物及其制备方法和应用
WO2014173029A1 (zh) 氮芥衍生物及其制备方法和肿瘤治疗应用
CN101314584A (zh) HGF/c-Met信号通道抑制剂及其制备方法和用途
CN102115474A (zh) 新型18F标记的吡唑并[1,5-a]嘧啶类化合物及制备和应用
CN103288809A (zh) 葛根素单磷酸盐或单磺酸盐衍生物及其制备方法
CN101967148B (zh) 新的18F取代对甲苯磺酰氧基标记的吡唑并[1,5-a]嘧啶类化合物及制备和应用
WO2025108336A1 (zh) 用于egfr蛋白降解的化合物及其用途
CN104945399A (zh) 一种莫西沙星杂质c的制备方法
CN104910080B (zh) 一种厄洛替尼相关物质及其制备方法
CN101318932A (zh) 2′-羧基-5′-氟联苯衍生物、其制备及应用
CN101245103A (zh) 斑蝥素人工抗原的制备方法
CN116332824A (zh) 一种杂环化合物及其制备方法和应用
CN104478863A (zh) 一种阿法替尼的制备方法
CN103254140A (zh) 新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用
CN101967149B (zh) 18F取代硝基标记的吡唑并[1,5-a]嘧啶类化合物及制备和应用
TW202510874A (zh) 一種大環化合物及其用途
CN105418593A (zh) 一种奥美沙坦酯关键中间体及奥美沙坦酯的制备方法
CN105481852A (zh) 7-苯并[b]-[1,10]邻菲咯啉对甲氧基苯甲酰胺基硫脲及其制备方法和用途
CN104277035B (zh) 吖啶-1，3，4-噻二唑类化合物及其制备方法和应用
CN114685508A (zh) 一种6-(5-氯-2-吡啶基)-吡咯并[3,4-b]吡嗪-5,7-二酮的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130619